论文部分内容阅读
目的:观察康艾注射液联合GP方案治疗局限晚期胰腺癌的疗效。方法:52例晚期胰腺癌患者,随机分为治疗组26例,男16例,女10例;对照组26例,男15例,女11例;对照组于1,8,15 d予以吉西他滨1 000 mg/m2 gtt,于4～6 d DDP30mg/m2(水化)gtt,28 d为1个周期。化疗2个周期;治疗组在对照组用药基础上于1～20 d加用康艾注射液50 mL加入5%葡萄糖500 mL中gtt,1次/d,1～20 d为1个周期,连用2个周期。两组均于治疗前及治疗2个周期后行CT或MRI检查;每周查血常规和生化全项1次。治疗2个周期后评价疗效及毒副反应。结果:治疗组近期疗效有效率和临床受益反应整体改善率明显优于对照组(P<0.05)。治疗组严重不良反应发生率明显低于对照组(P<0.05)。结论:康艾注射液联合GP方案治疗晚期胰腺癌疗效确切,值得推广。
Objective: To observe the curative effect of Kangai injection combined with GP regimen in the treatment of locally advanced pancreatic cancer. Methods: Fifty-two patients with advanced pancreatic cancer were randomly divided into treatment group (26 males and 16 females and 10 females), control group (26 males and 15 females and 11 females), and the control group received Gemcitabine 1 000 mg / m2 gtt, at 4 ~ 6 d DDP30mg / m2 (hydration) gtt, 28d for 1 cycle. 2 cycles of chemotherapy; the treatment group in the control group on the basis of medication plus Kang Ai injection 50 ~ 50mL 5mL glucose 500mL gtt, 1 / d, 1 ~ 20 d for 1 cycle, 2 cycles. Both groups were treated with CT or MRI before treatment and after 2 cycles of treatment. Blood routine and biochemical tests were performed once a week. After 2 cycles of treatment efficacy and toxicity were evaluated. Results: The overall effective rate of treatment and clinical benefit response in the treatment group was significantly better than that in the control group (P <0.05). The incidence of serious adverse reactions in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion: Kangai injection combined with GP regimen in the treatment of advanced pancreatic cancer is effective and worthy of promotion.